Literature DB >> 15222672

Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections.

Blair Capitano1, David P Nicolau, Brian A Potoski, Karin E Byers, Michael Horowitz, Raman Venkataramanan, David L Paterson.   

Abstract

The treatment of gram-negative infection of the central nervous system (CNS) presents a clinical challenge due to antibiotic resistance and difficulties with penetration into the cerebrospinal fluid (CSF). Two patients with gram-negative CNS infections were treated successfully with high-dose, prolonged infusions of meropenem. The CSF meropenem concentrations exceeded the minimum inhibitory concentration of the pathogen for virtually the entire dosing interval in both cases. Our experience demonstrates that dosage modification to maximize pharmacodynamic targets and bactericidal activity may be practically applied to optimize antibiotic treatment for difficult-to-treat CNS infections.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15222672     DOI: 10.1592/phco.24.8.803.36070

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  4 in total

1.  2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis.

Authors:  Allan R Tunkel; Rodrigo Hasbun; Adarsh Bhimraj; Karin Byers; Sheldon L Kaplan; W Michael Scheld; Diederik van de Beek; Thomas P Bleck; Hugh J L Garton; Joseph R Zunt
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

2.  Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA-Specified End Points.

Authors:  Antoni Torres; Doug Rank; David Melnick; Ludmyla Rekeda; Xiang Chen; Todd Riccobene; Ian A Critchley; Hassan D Lakkis; Dianna Taylor; Angela K Talley
Journal:  Open Forum Infect Dis       Date:  2019-04-25       Impact factor: 3.835

3.  Is Meropenem as a Monotherapy Truly Incompetent for Meropenem-Nonsusceptible Bacterial Strains? A Pharmacokinetic/Pharmacodynamic Modeling With Monte Carlo Simulation.

Authors:  Xiangqing Song; Yi Wu; Lizhi Cao; Dunwu Yao; Minghui Long
Journal:  Front Microbiol       Date:  2019-11-29       Impact factor: 5.640

4.  Population Pharmacokinetics and Dosing Regimen Optimization of Meropenem in Cerebrospinal Fluid and Plasma in Patients with Meningitis after Neurosurgery.

Authors:  Cheng Lu; Yuyi Zhang; Mingyu Chen; Ping Zhong; Yuancheng Chen; Jicheng Yu; Xiaojie Wu; Jufang Wu; Jing Zhang
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.